Mainz Biomed NV (MYNZ)
(Delayed Data from NSDQ)
$0.36 USD
+0.01 (3.40%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $0.36 0.00 (0.28%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
MYNZ 0.36 +0.01(3.40%)
Will MYNZ be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MYNZ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MYNZ
Absci Corporation (ABSI) Reports Q2 Loss, Lags Revenue Estimates
Fortress Biotech (FBIO) Reports Q2 Loss, Lags Revenue Estimates
MYNZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Lags Revenue Estimates
Adma Biologics (ADMA) Surpasses Q2 Earnings and Revenue Estimates
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
Other News for MYNZ
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
Mainz Biomed launches enhanced ColoAlert product
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
Mainz Biomed Provides Half Year 2024 Corporate Update